BioInvent Reports the Enrollment of First Patient in P-I/IIa Study of BI-1206 + Keytruda for Solid Tumors

Shots:

• The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen
• The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of Keytruda, and part B, which will explore the activity of the combination regimen in patients with advanced lung cancer, melanoma and other types of malignancies
• The study will be conducted at multiple sites across the US & EU and will assess its antitumoral activity, as well as explore the expression of potential immunological markers that might predict clinical responses. BI-1206 is a mAb targeting FcgRIIb, currently being evaluated in patients with NHL

Click here to read full press release/ article | Ref: BioInvent | Image: Merck